AI-Assisted Management of Diabetes and Hypertension in Primary Care

November 11, 2026 updated by: Jiangsu Taizhou People's Hospital

Brief Summary:

Many older adults in rural areas suffer from both type 2 diabetes and high blood pressure. Managing these two conditions at the primary care level is often challenging. This study aims to find out if a new "village doctor-led digital management model" can help improve patient health compared to the current standard care.

Who can participate? Adults aged 60 or older who have been diagnosed with both type 2 diabetes and high blood pressure, whose current blood sugar or blood pressure is not well-controlled, and who receive care at local village clinics.

How does the study work?

Village clinics will be randomly assigned to one of two groups:

Usual Care Group: Patients receive standard national primary health services.

Integrated Care Group: In addition to standard care, village doctors will use an Artificial Intelligence (AI) system. This system provides clinical suggestions to the village doctors, helps arrange remote consultations with hospital specialists if needed, and gives patients personalized advice on diet and exercise.

What are we measuring? We will follow participants for up to 3 years. The main goals are to see if the new AI-assisted model improves the control of blood sugar, blood pressure, and cholesterol at 12 months, and whether it reduces the risk of severe cardiovascular events (like heart attacks or strokes) over 36 months.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

9245

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

IInclusion Criteria:

Age ≥ 60 years. Previously diagnosed with both type 2 diabetes mellitus and hypertension. Inadequate glycemic control (HbA1c ≥ 7.5%; or HbA1c ≥ 8.0% if accompanied by clinical cardiovascular disease) OR inadequate blood pressure control (systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg).

Signed a family doctor service agreement with the local village doctor. Agree to participate in the study and provide written informed consent.

Exclusion Criteria:

Severe physical or psychological problems. Unable to attend on-site visits. Unable to answer questions independently. Unable to reside in the participating community for more than 1 year. Life expectancy less than 3 years. Participated in any other clinical trial within the past 6 months.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Integrated Care Group

Village doctor-led integrated digital management, including LLM-assisted decision support, remote specialist collaboration, and individualized lifestyle intervention.

A digital platform that integrates patient data and uses a large language model to provide risk alerts and management suggestions to village doctors for review.

Village doctors can initiate remote consultations with specialists (e.g., endocrinology, cardiology) through the platform for complex or poorly controlled cases.

Usual care according to the National Basic Public Health Service requirements.

Other: Usual Care Group

Usual care according to the National Basic Public Health Service requirements.

Usual care according to the National Basic Public Health Service requirements.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of participants achieving at least 2 of 3 ABC goals at 12 months
Time Frame: 12 months post-randomization

The proportion of participants achieving at least two of the following three predefined goals at 12 months post-randomization: A (HbA1c control), B (Blood pressure control), and C (LDL-C control).

12 months post-randomization
Time to first Major Adverse Cardiovascular Event (MACE) within 36 months
Time Frame: Up to 36 months post-randomization

The time from randomization to the first occurrence of a Major Adverse Cardiovascular Event (MACE) within 36 months.

Up to 36 months post-randomization

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 14, 2026

Primary Completion (Estimated)

November 14, 2029

Study Completion (Estimated)

November 14, 2029

Study Registration Dates

First Submitted

October 27, 2026

First Submitted That Met QC Criteria

November 11, 2026

First Posted (Actual)

November 17, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 11, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • LSKY 2026 -174-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.